Cartesian Therapeutics, Inc.

Cartesian Therapeutics is banking on both positive mid-stage data for Descartes-08 as well as a manufacturing process designed to cut down on logistical hurdles and toxicity in order to make its CAR-T

The number of biopharmaceutical company initial public offerings in the US dropped considerably from the first quarter to the second quarter, but with 12 IPOs during the first half of 2024 the market

Cartesian Therapeutics, Inc. has positive data from a Phase IIb trial testing Descartes-08, an autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy directed against the B-cell

Astellas Pharma, Inc. has a sharp eye on deal-making opportunities, including for late-stage assets, but a thrust on launch execution for key products and controlling expenses is where much of the ac